Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study-Reference-Cited by-同舟云学术

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Published:2019-10-16 Issue:2 Volume:26 Page:354-363
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Hui Rina,Pearson Alex^ORCID,Cortes Javier^ORCID,Campbell Christine^ORCID,Poirot Camille,Azim Hatem A.,Fumagalli Debora^ORCID,Lambertini Matteo^ORCID,Daly Fergus,Arahmani Amal,Perez-Garcia José,Aftimos Philippe,Bedard Philippe L.^ORCID,Xuereb Laura,Scheepers Elsemieke D.,Vicente Malou^ORCID,Goulioti Theodora,Loibl Sibylle,Loi Sherene^ORCID,Pierrat Marie-Jeanne,Turner Nicholas C.,Andre Fabrice,Curigliano Giuseppe^ORCID

Funder

Institut de Recherches Internationales Servier

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies;Bioorganic Chemistry;2024-11

2. Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance;Frontiers in Oncology;2024-07-08

3. Redefining the significance of quinoline containing compounds as potent VEGFR-2 inhibitors for cancer therapy;Medicinal Chemistry Research;2024-06-27

4. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

5. Exploring FGFR signaling inhibition as a promising approach in breast cancer treatment;International Journal of Biological Macromolecules;2024-05